Impact of BRCA mutation on the survival and risk of contralateral breast cancer in Asian breast cancer patients

乳腺癌 医学 肿瘤科 内科学 BRCA突变 三阴性乳腺癌 危险系数 癌症 外科肿瘤学 种系突变 突变 置信区间 生物 遗传学 基因
作者
Po‐Han Lin,Shin‐Cheh Chen,Ling‐Ming Tseng,King‐Jen Chang,Ai-Chu Huang,Kuo‐Chih Cheng,Karen Yang,Hui‐Chen Wu,Tsu‐Yi Chao,Yuan‐Ching Chang,Peng‐Chan Lin,Wen‐Hung Kuo,Wen-Lin Kuo,Ching‐Hung Lin,Huo-Mu Chen,Dah‐Cherng Yeh,Liang‐Chih Liu,Chun‐Yu Liu,Mingyang Wang,Chiao Lo
出处
期刊:Breast Cancer Research and Treatment [Springer Science+Business Media]
卷期号:192 (3): 629-637 被引量:7
标识
DOI:10.1007/s10549-021-06446-7
摘要

Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations.A total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical-pathologic characteristics, survival, and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method.The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, p < 0.001). The risk of CBC was significantly higher in BRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients.Our study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Singularity发布了新的文献求助10
1秒前
怡然的沁完成签到,获得积分20
1秒前
1秒前
冬至完成签到,获得积分10
2秒前
小曹君完成签到,获得积分10
2秒前
Zutter发布了新的文献求助10
2秒前
科研通AI6.2应助hdc12138采纳,获得10
2秒前
Eunectes完成签到 ,获得积分10
3秒前
荣念云发布了新的文献求助20
3秒前
xy完成签到,获得积分10
4秒前
江屿发布了新的文献求助20
4秒前
4秒前
4秒前
时尚的哈密瓜完成签到,获得积分10
4秒前
大模型应助Tumbleweed668采纳,获得10
4秒前
QQ完成签到 ,获得积分10
5秒前
5秒前
烟雨完成签到,获得积分10
6秒前
lwz完成签到,获得积分10
6秒前
喃恬完成签到,获得积分10
6秒前
seven完成签到,获得积分10
7秒前
冷静的之卉完成签到,获得积分10
7秒前
ben完成签到,获得积分10
7秒前
Jeremiah完成签到,获得积分10
7秒前
7秒前
7秒前
酷波er应助jiayou采纳,获得10
7秒前
7秒前
8秒前
含糊的水卉完成签到,获得积分20
8秒前
斯文败类应助粘豆包采纳,获得10
8秒前
发一篇sci完成签到 ,获得积分10
9秒前
执着银耳汤完成签到,获得积分10
9秒前
认真金鱼完成签到,获得积分10
9秒前
9秒前
Yan完成签到,获得积分10
9秒前
个性的海之完成签到,获得积分10
9秒前
10秒前
第一俗人完成签到,获得积分10
10秒前
board_Gu完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Developing Genetic Editing Tools for Lysobacter 2000
Моделирование процессов самоорганизации в кристаллообразующих системах 1000
History of U.S. Space Surveillance and Satellite Cataloging 1000
Adhesion Science: Principles & Practice 800
Signals, Systems, and Signal Processing 610
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6523609
求助须知:如何正确求助?哪些是违规求助? 8316651
关于积分的说明 17796513
捐赠科研通 5625489
什么是DOI,文献DOI怎么找? 2928263
邀请新用户注册赠送积分活动 1905081
关于科研通互助平台的介绍 1765086